



Resolution

of the Federal Joint Committee on an Amendment of the
Pharmaceuticals Directive:
Annex XII – Benefit Assessment of Medicinal Products with
New Active Ingredients according to Section 35a (SGB V)
Crizanlizumab (repeal of the resolution of 20 May 2021)

of 19 October 2023

At its session on 19 October 2023, the Federal Joint Committee (G-BA) resolved to amend the Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

- I. **The findings on the benefit assessment of the active ingredient Crizanlizumab in Annex XII of the Pharmaceuticals Directive in the version of the resolution of 20 May 2021 (BAnz AT 24.06.2021 B5) are repealed.**

- II. **The resolution will enter into force on the day of its publication on the website of the G-BA on 19 October 2023.**

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 19 October 2023

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken